Leerink Partnrs Issues Optimistic Forecast for JAZZ Earnings

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the specialty pharmaceutical company will post earnings of $16.57 per share for the year, up from their prior forecast of $16.47. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.95 per share.

Several other research firms also recently commented on JAZZ. Piper Sandler restated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, TD Cowen lowered their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ JAZZ opened at $124.27 on Thursday. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 0.87 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The business’s 50 day moving average is $122.74 and its two-hundred day moving average is $115.76.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,253 shares of company stock valued at $1,001,434 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares in the last quarter. UMB Bank n.a. raised its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares in the last quarter. Ellsworth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after purchasing an additional 149 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock worth $868,000 after purchasing an additional 155 shares in the last quarter. Finally, Cooper Financial Group lifted its stake in Jazz Pharmaceuticals by 3.7% during the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 156 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.